Sam Campbell
About Sam Campbell
Sam Campbell is the Chairman of CritiTech with over 30 years of experience in executive leadership and investment management in early-stage life science companies.
Sam Campbell's Executive Leadership at CritiTech
Sam Campbell has been Chairman of CritiTech since 2003, bringing more than 30 years of executive leadership and investment management experience to the early-stage life science company. His extensive background includes critical roles and decision-making capabilities that drive the company's strategic direction and growth. Campbell's leadership has helped position CritiTech as a significant player in the life sciences field.
Sam Campbell's Career at Campbell-Becker
Prior to his role at CritiTech, Sam Campbell served as President of Campbell-Becker. In this capacity, he was responsible for overseeing the firm’s operations and guiding its investment strategies. His tenure at Campbell-Becker further solidified his expertise in managing and growing early-stage life science companies, providing him with valuable industry insights and leadership skills.
Sam Campbell's Education and Expertise
Sam Campbell holds an M.B.A. and a B.A. in Business & History from the University of Kansas. His academic background in business and history has equipped him with a deep understanding of both the historical and contemporary aspects of business management. This education has been fundamental in shaping his approach to leadership and investment management in the life sciences sector.
Lawrence Life Sciences Center Development
Sam Campbell played a crucial role in developing the Lawrence Life Sciences Center. This facility is part of the largest university-based incubator in the Midwest, aimed at fostering innovation and entrepreneurship in the life sciences. The center provides essential resources and support for emerging life science companies, underscoring Campbell's commitment to advancing the field through strategic infrastructure development.
Board Memberships and Industry Contributions
Sam Campbell currently serves on the Boards of NanOlogy, LLC, an oncology drug development company, and the University National Bank. His participation in these boards highlights his ongoing influence and contributions to the fields of drug development and finance. His insights and governance help these organizations achieve their objectives and sustain growth.